In addition to the favorable effects on many co-morbidities related to heart failure, including diabetes, obesity and hypertension, the sodium excretion and osmotic diuresis associated with SGLT2 inhibitors could also contribute to a reduced risk of heart failure [44–46]. This evidence concerns the gene SLC5A2 and obesity disorder.